康弘药业(002773.SZ)获得布瑞哌唑片药品注册证书

Core Viewpoint - Kanghong Pharmaceutical (002773.SZ) has received the Drug Registration Certificate for Brexpiprazole Tablets from the National Medical Products Administration, indicating regulatory approval for the treatment of schizophrenia [1] Group 1 - The Drug Registration Certificate numbers are 2025S03922 and 2025S03923 [1] - Brexpiprazole's mechanism of action in treating schizophrenia is not fully understood, but it may involve partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, along with antagonist activity at serotonin 5-HT2A receptors [1]